ProCE Banner Activity

Frequently Asked Questions on the Management of Hepatitis B

Clinical Thought
How long should patients with chronic hepatitis B be treated with nucleos(t)ide analogues? When should we treat patients with immune-tolerant hepatitis B? Here’s my take.

Released: December 04, 2019

Expiration: December 02, 2020

Share

Faculty

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Program Director Disclosure

Program Director

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul K. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Conatus, Dova, EdiGene, Eisai, Ferring, Gilead Sciences, Quest, and Surrozen; has received funds for research support from Allergan, Assembly, Gilead Sciences, La Jolla, and HCV-TARGET Registries; and has ownership interest in Durect.